← Back to Screener
Armata Pharmaceuticals, Inc. Common Stock (ARMP)
Price$12.50
Favorite Metrics
Price vs S&P 500 (26W)254.03%
Price vs S&P 500 (4W)27.57%
Market Capitalization$421.28M
All Metrics
Book Value / Share (Quarterly)$0.53
P/TBV (Annual)1.74x
Revenue Growth (3Y)-3.81%
Cash Flow / Share (Quarterly)$-0.72
Price vs S&P 500 (YTD)78.98%
Net Profit Margin (TTM)-3544.03%
EPS (TTM)$-4.79
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-4.79
Revenue Growth (5Y)43.00%
EPS (Annual)$-4.80
ROI (Annual)-102.33%
Net Profit Margin (5Y Avg)-1324.46%
Cash / Share (Quarterly)$0.24
Revenue Growth QoQ (YoY)-12.15%
ROA (Last FY)-226.06%
Revenue Growth TTM (YoY)-5.22%
EBITD / Share (TTM)$-0.97
ROE (5Y Avg)-117.52%
Operating Margin (TTM)-747.02%
Cash Flow / Share (Annual)$-0.72
P/B Ratio22.06x
P/B Ratio (Quarterly)2.16x
Net Income / Employee (Annual)$-3
EV / Revenue (TTM)136.52x
Net Interest Coverage (TTM)-0.27x
ROA (TTM)-207.87%
EPS Incl Extra (Annual)$-4.80
Current Ratio (Annual)1.19x
Quick Ratio (Quarterly)1.02x
3-Month Avg Trading Volume0.05M
52-Week Price Return874.58%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.24
P/S Ratio (Annual)85.90x
Asset Turnover (Annual)0.06x
52-Week High$16.34
Operating Margin (5Y Avg)-740.17%
EPS Excl Extra (Annual)$-4.80
CapEx CAGR (5Y)-7.95%
Tangible BV CAGR (5Y)56.05%
26-Week Price Return262.78%
Quick Ratio (Annual)1.02x
13-Week Price Return101.75%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.19x
Enterprise Value$669.51
Revenue / Share Growth (5Y)22.08%
Asset Turnover (TTM)0.06x
Book Value / Share Growth (5Y)-38.52%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3544.03%
Cash / Share (Annual)$0.24
3-Month Return Std Dev108.03%
Net Income / Employee (TTM)$-3
ROE (Last FY)-102.33%
Net Interest Coverage (Annual)-0.20x
EPS Basic Excl Extra (Annual)$-4.80
Receivables Turnover (TTM)4.70x
Total Debt / Equity (Quarterly)1.38x
EPS Incl Extra (TTM)$-4.79
Receivables Turnover (Annual)4.17x
ROI (TTM)-81.23%
P/S Ratio (TTM)85.90x
Pretax Margin (5Y Avg)-1324.46%
Revenue / Share (Annual)$0.14
Tangible BV / Share (Annual)$0.71
Price vs S&P 500 (52W)839.48%
Year-to-Date Return83.12%
5-Day Price Return-1.63%
EPS Normalized (Annual)$-4.80
ROA (5Y Avg)-77.97%
Net Profit Margin (Annual)-3544.03%
Month-to-Date Return12.30%
Cash Flow / Share (TTM)$-1.62
EBITD / Share (Annual)$-0.97
Operating Margin (Annual)-747.02%
LT Debt / Equity (Annual)0.38x
ROI (5Y Avg)-116.66%
LT Debt / Equity (Quarterly)0.38x
EPS Basic Excl Extra (TTM)$-4.79
P/TBV (Quarterly)4.68x
P/B Ratio (Annual)1.24x
Pretax Margin (TTM)-3544.03%
Book Value / Share (Annual)$1.00
Price vs S&P 500 (13W)98.89%
Beta1.50x
Revenue / Share (TTM)$0.13
ROE (TTM)-120.00%
52-Week Low$1.11
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.13
4.13
4.13
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ARMPArmata Pharmaceuticals, Inc. Common Stock | 85.90x | -5.22% | — | — | $12.50 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 11.09x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Armata Pharmaceuticals develops bacteriophage therapeutics to treat antibiotic-resistant bacterial infections using proprietary phage-based technology. The company has clinical-stage candidates targeting major pathogens including Pseudomonas aeruginosa and Staphylococcus aureus, with additional programs in development. Armata is also collaborating with Merck on synthetic phage candidates for an undisclosed infectious disease target, diversifying its pipeline across difficult-to-treat infections.